摘要
目的观察鼻敏感方对变应性鼻炎模型大鼠的影响,探讨鼻敏感方治疗变应性鼻炎可能的作用机制。方法取SD大鼠48只,随机分为空白对照组,模型组,鼻敏感方高、中、低剂量组(20,10,5 g·kg-1·d-1),氯雷他定组(1.67 mg·kg-1·d-1),共6组,每组8只。以卵清蛋白为致敏原建立大鼠变应性鼻炎模型,观察各组大鼠行为表现,测定白细胞介素-4(IL-4)和干扰素-γ(IFN-γ)细胞因子水平,观察鼻黏膜病理形态变化。结果与模型组比较,鼻敏感方各剂量组及氯雷他定组鼻痒、喷嚏、清涕等症状明显减轻(P<0.01),鼻黏膜炎症程度减轻(P<0.05),血清IFN-γ水平升高,IL-4水平降低(P<0.01)。结论鼻敏感方可显著改善大鼠鼻部症状,减轻鼻黏膜炎症程度,影响IL-4、IFN-γ水平,对AR病理模型具有较好的疗效。
Objective To observe the effect of Bi Mingan Recipe(BMR)on serum IL-4 and IL-γ levels in rats with allergic rhinitis(AR),and to explore its possible therapeutic mechanism. Methods A total of 48 SD rats were evenly divided into 6 groups, blank group, model group, loratadine group(1.67 mg·kg-1·d-1), and high-dose,middle-dose and low-dose BMR group(in the dosage of 20,10,5 g·kg^-1·d^-1). Except the blank group,other groups were given OVA to induce AR. After the model had been established, blank group and model group were given intragastic infusion with normal saline,and the medication groups were given orally the corresponding medicine. And then we observed the behavior performance of rats,detected the cytokine IL-4 and IFN-γ levels,and observed the pathological changes of nasal mucosa. Results In the four medication groups,symptoms of rhinocnesmus,sneezing,thin nasal discharge were obviously relieved compared with the model group(P〈0.01),the inflammatory degree of pathologic nasal mucosa was relieved(P〈0.05), serum IFN-γ level was obviously increased, and IL-4 was decreased as compared with the model group(P〈0.01). Conclusion Bi Mingan Recipe has obvious effect on relieving the nasal symptoms of allergic rhinitis rat and relieve the inflammatory degree of pathologic nasal mucosa,and its possible mechanism in treating allergic rhinitis is adjusting the balance of Th17/Treg cells by influencing the IL-4,IFN-γ levels. Th17/Treg cells have significant correlation with IL-4 and IFN-γ levels, suggesting that IL-4 and IFN-γ play an important role in the pathogenesis of allergic rhinitis.
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2015年第3期338-341,355,共5页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
江苏省中医药局暨康缘中医药科技创新基金(HZ1001KY)